Previous close | 14.75 |
Open | 14.76 |
Bid | 14.74 x 300 |
Ask | 14.81 x 200 |
Day's range | 14.75 - 14.85 |
52-week range | 11.53 - 15.89 |
Volume | |
Avg. volume | 108,200 |
Market cap | 214.635M |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 13 Dec 2019 |
1y target est | N/A |
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., February 13, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC).